Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

PHASE2TerminatedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

September 29, 2025

Study Completion Date

October 19, 2025

Conditions
Persistent Corneal Epithelial Defect
Interventions
DRUG

KPI-012

KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

DRUG

KPI-012 Vehicle

KPI-012 formulation with no active drug

Trial Locations (46)

10036

Principal Investigator, New York

11570

Principal Investigator, Rockville Centre

15219

Principal Investigator, Pittsburgh

19107

Principal Investigator, Philadelphia

23502

Principal Investigator, Norfolk

25606

Principal Investigator, Morgantown

27529

Principal Investigator, Garner

27710

Principal investigator, Durham

30339

Principal Investigator, Atlanta

32763

Principal Investigator, Orange City

33136

Principal Investigator, Miami

33143

Principal Investigator, Miami

36301

Principal Investigator, Dothan

37215

Principal Investigator, Nashville

38119

Principal Investigator, Memphis

40206

Principal Investigator, Louisville

43065

Principal Investigator, Powell

46260

Principal Investigator, Indianapolis

46290

Principal Investigator, Carmel

53142

Principal Investigator, Kenosha

57701

Principal Investigator, Rapid City

63017

Principal Investigator, Chesterfield

63131

Principal Investigator, St Louis

64111

Principal Investigator, Kansas City

64133

Principal Investigator, Kansas City

77030

Principal Investigator, Houston

78212

Principal Investigator, San Antonio

78712

Principal Investigator, Austin

78731

Principal Investigator, Austin

80045

Principal Investigator, Aurora

80120

Principal Investigator, Littleton

80528

Principal Investigator, Fort Collins

90013

Principal Investigator, Los Angeles

90095

Principal Investigator, Los Angeles

91107

Principal Investigator, Pasadena

92037

Principal Investigator, La Jolla

92354

Principal Investigator, Loma Linda

92897

Principal Investigator, Irvine

95670

Principal Investigator, Rancho Cordova

98119

Principal Investigator, Seattle

02111

Principal Investigator, Boston

02114

Principal Investigator, Boston

07650

Principal Investigator, Palisades Park

C1428ARF

Principal Investigator, Caba

S2000

Principal Investigator, Rosario

00921

Principal Investigator, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Kala Pharmaceuticals, Inc.

INDUSTRY

lead

Combangio, Inc

INDUSTRY